Sugi Predict

Sugi Predict / Targets / MPL

MPL

Thrombopoietin receptor · P40238 · MPL on Sugi Atlas →

23,493 patent compounds predicted against MPL, 10,282 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1091019 SCHEMBL1091019 1.00 20/20
SCHEMBL1092004 SCHEMBL1092004 1.00 20/20
SCHEMBL1092178 SCHEMBL1092178 1.00 20/20
SCHEMBL1102030 SCHEMBL1102030 1.00 20/20
SCHEMBL1102039 SCHEMBL1102039 1.00 20/20
SCHEMBL1102044 SCHEMBL1102044 1.00 20/20
SCHEMBL1102045 SCHEMBL1102045 1.00 20/20
SCHEMBL1102074 SCHEMBL1102074 1.00 20/20
SCHEMBL1102093 SCHEMBL1102093 1.00 20/20
SCHEMBL1102037 SCHEMBL1102037 0.91 20/20
SCHEMBL1102087 SCHEMBL1102087 0.85 20/20
SCHEMBL1102046 SCHEMBL1102046 0.80 20/20
SCHEMBL1102042 SCHEMBL1102042 0.78 20/20
SCHEMBL1091929 SCHEMBL1091929 0.77 20/20
SCHEMBL1102034 SCHEMBL1102034 0.75 20/20
SCHEMBL1090937 SCHEMBL1090937 0.73 20/20
SCHEMBL1102033 SCHEMBL1102033 0.70 20/20
SCHEMBL1102075 SCHEMBL1102075 0.69 20/20
SCHEMBL1091880 SCHEMBL1091880 0.67 20/20
SCHEMBL1091987 SCHEMBL1091987 0.66 20/20

Clinical trials — most relevant to MPL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA PHASE4UNKNOWN
Outcomes in Bone Marrow Aplasia. PHASE3NOT_YET_RECRUITING
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. PHASE3WITHDRAWN
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia PHASE2/PHASE3COMPLETED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer PHASE3COMPLETED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients PHASE3COMPLETED
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA PHASE3UNKNOWN
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT PHASE2COMPLETED
Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia PHASE2UNKNOWN
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia PHASE2UNKNOWN
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients PHASE2COMPLETED
Extended Dosing With Eltrombopag for Severe Aplastic Anemia PHASE2COMPLETED
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) PHASE2COMPLETED
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia PHASE2COMPLETED
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome PHASE2UNKNOWN
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) PHASE2COMPLETED
Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia PHASE2COMPLETED
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) PHASE2RECRUITING
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation PHASE2UNKNOWN
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) PHASE2RECRUITING
The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients PHASE2COMPLETED
A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia PHASE2COMPLETED
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors PHASE1SUSPENDED
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease PHASE1UNKNOWN
Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital nanUNKNOWN
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura nanNOT_YET_RECRUITING
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients nanNOT_YET_RECRUITING
TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients. nanCOMPLETED
Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MPL binder may also engage these)

ProteinNameSimilarity
Q08351 — 1.000 Q08351 →
CSF3R Granulocyte colony-stimulating factor receptor 0.994 landscape →
Q07303 — 0.992 Q07303 →
P14753 — 0.990 P14753 →
P26954 — 0.989 P26954 →
Q60837 — 0.988 Q60837 →
P40321 — 0.987 P40321 →
P40223 — 0.986 P40223 →
Q01114 — 0.986 Q01114 →
Q61826 — 0.986 Q61826 →
P22272 — 0.986 P22272 →
Q9HC73 — 0.986 Q9HC73 →
P34902 — 0.985 P34902 →
EPOR Erythropoietin receptor 0.985 landscape →
P22273 — 0.984 P22273 →
Q6UWB1 — 0.984 Q6UWB1 →
Q95118 — 0.984 Q95118 →
O70540 — 0.983 O70540 →
P42701 — 0.983 P42701 →
A5PJC7 — 0.983 A5PJC7 →
P26955 — 0.982 P26955 →
P32927 — 0.981 P32927 →
Q96F46 — 0.981 Q96F46 →
Q8MJS1 — 0.981 Q8MJS1 →
A0AAU7VAE8 — 0.980 A0AAU7VAE8 →
P0C6B3 — 0.980 P0C6B3 →
Q8IU57 — 0.980 Q8IU57 →
Q2KL21 — 0.979 Q2KL21 →
Q9MYZ9 — 0.979 Q9MYZ9 →
Q96BF3 — 0.978 Q96BF3 →